Legend Biotech (LEGN) Shakes Up Board

Group 1 - Legend Biotech Corp (NASDAQ:LEGN) is recognized as one of the 13 Best Revenue Growth Stocks to buy currently [1] - The company appointed Robin Meng, chairman and executive director of major shareholder GenScript, as a Class III director, replacing Li Zhu [1] - Directors Li Zhu and Yau Wai Man Philip resigned from the board, with the company stating that these departures were not related to any operational or policy disputes [3] Group 2 - H. C. Wainwright lowered the price target for Legend Biotech's stock from $60 to $50, while TD Cowen downgraded the stock from Buy to Hold with a price target of $21 [3] - Legend Biotech reported preliminary net trade sales of approximately $555 million for its CARVYKTI multiple myeloma cell therapy for the quarter ended December 31, 2025 [3] - The company is engaged in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications [3]